Net Net Stock Overview

Subscribe

To see hundreds more international net nets, consider subscribing

Overview

Amylyx Pharmaceuticals Inc
Healthcare
P/NCAV
0.36x
Ticker
AMLX
Exchange
NASDAQ
Country
United States
Close
1.95 $
Mkt Cap
136.1M $
EV
-34.1M $
NCAV Burn Rate
-14.9%
Current Ratio
5.66
Debt/Equity
0.0
EV/REV
-0.09x
EV/EBIT
-0.9x
EV/FCF
-2.6x
Dilution
5.5% p.A
Total Net Income
-293.0M $
Cheapness
100.0%
Amylyx Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in the discovery and development of treatments for neurodegenerative diseases. The Company is focused on the development and commercialization of its product candidate, AMX0035 (sodium phenylbutyrate and taurursodiol, also known as ursodoxicoltaurine) for the treatment of amyotrophic lateral sclerosis (ALS). RELYVRIO (also known as AMX0035), an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol is approved to treat ALS in adults in the United States. AMX0035 is a dual unfolded protein response (UPR)-Bax apoptosis inhibitor composed of PB and TURSO (also known as TUDCA). Its development of antisense oligonucleotides (ASOs), including lead ASO AMX0114, which targets calpain-2 (CAPN2), a gene encoding calcium-dependent proteolytic enzyme which has been implicated in the pathogenesis of ALS and other neurodegenerative diseases.

Profitability

positive values --- Average negative values

Margins

--- Average

Valuation

positive values --- Average negative values

Dilution

--- Average